It’s not just for diabetes anymore

GLP-1 receptor agonists [semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)] are proving transformational for type II diabetes patients in particular and for obese individuals in general. Now, it appears they have benefits in cancer patients. “Use of GLP-1 receptor agonists in patients with four solid tumor types was significantly associated with lower rates of progression […]